Haematopoietic stem cell transplantation (HSCT) is a form of transfusion, and donors are screened for diseases transmissible by transfusion. Syphilis exposure is screened by either Venereal Disease Research Laboratory (VDRL) test or Treponema pallidum Haemagglutination Assay, and confirmed by Fluorescent Treponema Antibody (FTA-Abs) test. Positive donors are traced and referred. HSCT recipients are also screened for baseline documentation and to avoid exacerbation of latent syphilis during stem cell transplantation (SCT). Between 1989 and 2004, 845 consecutive adult HSCT were performed in Queen Mary Hospital (male to female 1.28 to 1, median age 36 years, range 16-67), including 178 autologous and 667 allogeneic HSCT. The donors (male to female 1.23 to 1, median age 35 years, range 9-58) were either siblings (n ¼ 554), unrelated donors (n ¼ 103) and parental or children donors (n ¼ 10). Commercial kits were used for the detection of VDRL reactivity (Becton Dickinson, Maryland, USA) and FTA-Abs (Trepo-Spot IF, bioMerieux, Marcy I' Etoile, France). Spirochaete detection in biopsy specimens was performed by silver staining and dark field microscopy. One case each of VDRL-positive recipient (0.12%) and donor (0.15%) were detected.
Case 1: A 42-year-old Nepalese man underwent allogeneic HSCT for chronic myeloid leukaemia in accelerated phase. Screening for VDRL (1:32) and confirmation by FTA-Abs were positive and he volunteered regular venereal exposure. He was treated with intramuscular benzthine penicillin G 2.4 MU weekly for 3 weeks with undetectable VDRL titre, while the marrow was cryopreserved from sibling donor coming over from Nepal. However, VDRL titres increased again (1:32) during conditioning 3 months later. The patient volunteered interval venereal exposure and he was re-treated with one dose of benzthine penicillin 2.4 MU and 2 weeks of ceftriaxone 1 g daily (day À7 to 7) when VDRL titre became undetectable. He engrafted on day 17 with grade IV GVHD of skin and liver (bilirubin: 560 mmol/l, normal 7-19; SGOT/GPT: 197/474 U/l, normal 12-28/5-31). A liver biopsy showed GVHD with negative viral and spirochaete detection. He continued to suffer from cholestasis, haemorrhagic cystitis and severe GVHD, despite treatment with steroids and azathioprine. Repeat testing for FTA-Abs and VDRL post-HSCT remained negative. At 6 months follow-up, he presented with a fungating penile mass, fever and hepatitis after venereal exposure. Skin and liver biopsy showed disseminated Trichosporon beigelii fungal infection without evidence of syphilis or other venereal infections. He died despite intensive anti-fungal treatment.
Case 2: A 27-year-old Chinese man with acute myeloid leukaemia with t(8;21) in second remission received allogeneic HSCT under famciclovir coverage for hepatitis B virus (HBV) carriage. Donor screening in his HLAidentical sister showed positivity for HBV as well as VDRL and FTA-Abs. Contact tracing revealed infection and exposure in her spouse, and both were treated with intramuscular penicillin G (24 MU Â 2 weekly doses). Bone marrow was harvested 1 month later and infused fresh and unmanipulated. The patient engrafted on day 18 with grade III acute GVHD of skin and liver (bilirubin 194 mmol/l, SGOT/GPT 359/304 IU/l). A liver biopsy showed GVHD features with minimal HBV staining and no spirochaetes, and he responded to steroid treatment. At 7-year follow-up, he is well in molecular remission with mild chronic GVHD. Serial testing of VDRL remained negative, but FTA-Abs unexpected turned positive after 60 months. On the detailed questioning, the patient admitted to venereal exposure and repeated treatment for genital warts and herpes after SCT, and Treponema exposure was attributed to treated post-SCT venereal infection.
The value of VDRL testing in blood, tissue and solid organ donors has been debated. 1 For blood donors, VDRL testing is mandatory by FDA standards since 1958. It is, however, no longer effective as a surrogate marker for HIV. Positivity may be caused by noninfective serological scars or crossreactions, and a negative result cannot exclude primary syphilis. Transfusion-related syphilis had not been reported in USA or Europe for 30 years. Apart from donor testing, other contributory factors included the use of stored blood, reduced syphilis incidence, widespread antibiotic use and unit exclusion by other viral markers. 1 It is possible that the theoretical transmission risk is too low to warrant exclusion of 'adequately treated' VDRLpositive individuals from the donor pool. Nevertheless, the pool is relatively adequate and VDRL-positive units are discarded by blood banks in most countries. Positive donor rates ranged from 0.2% in the West to over 12% in Africa. In Asian countries, it varied from 0.12 to 0.24%, with lower figures from voluntary donors. 2 For tissue harvests, despite common false positivity in post-mortem cadaveric donors, VDRL positivity is an FDA-stipulated exclusion criterion to collection. Up to 5% of skin and corneal harvests may be discarded. 3 For solid organ transplantation, unlike blood and tissue collection, VDRL positivity is not an absolute contraindication for donation. The use of antibiotic prophylaxis in donors and recipients allows reasonably safe solid organ transplants. 4, 5 By 2004 FDA guidelines, VDRL testing is mandatory for all stem cell donors, although related seropositive family donors are not absolutely excluded from making life-saving donations. Stem cells may either be infused unmanipulated or after cryopreservation. Fresh blood product infusion may increase syphilitic transmission risks. 1 Even in cryopreserved products, prolonged survival of spirochaetes is also possible. 6 Hence, adequate treatment of infected donors is essential. An additional theoretical problem in using seropositive donors is that transient false VDRL positivity due to the infusion of donor plasma 7 or engraftment of donor lymphocytes 8 may confuse the investigation of post-HSCT complications. 9 Our cases may be informative on some of syphilis-related issues in HSCT. Firstly, we did not find any evidence of HSCTrelated transmission or reactivation of syphilitic activity. Furthermore, donor and recipient FTA-Abs positivity did not persist in both patients after HSCT, probably due to novel immunoreconstitution. Secondly, although syphilitic hepatitis has been reported in transplant recipients, 9 the severe hepatic GVHD in both cases appeared to be unrelated to spirochaete infection. Thirdly, in our experience, post-SCT venereal exposure may not be uncommon, and it can be difficult to distinguish such syphilitic exposure from HSCT-related transmission. Hence, patients and donors with VDRL positivity should be adequately treated well before HSCT and retested for re-exposure before conditioning. 10 With refractory lifestyle habits, physicians should be aware of venereal risks after HSCT in such patients. 
